Saturday 17 October 2026
Export DMRA’s income statement to Excel — free account
Galecto, Inc.
DMRA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 85.0% and free cash flow fell 877.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
18.42
0.32
−1.71%
Follow DMRA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(114.81%) | 6.72% | (12.37%) | (26.26%) | |
| (92.89%) | (3.90%) | (8.79%) | (18.64%) | ||
ROIC |
(2,537.09%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(219.93%) | (2.25%) | (4.73%) | (10.07%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(9.21) | (4.93) | (0.73) | (0.73) | |
Free Cash Flow |
(12.23) | (6.73) | (24.88) | (44.51) | |
| Other line items | |||||
Cash ROIC |
(78.32%) | (1.35%) | (2.38%) | (4.21%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.77 | 1.24 | 1.03 | 0.86 | |
Depreciation/Fixed assets |
0.51 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(9.21) | (4.93) | (0.73) | (0.73) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates